MONTE ROSA THERAPEUTICS INC (GLUE) Stock Analyst Earnings Estimates
NASDAQ:GLUE - Nasdaq - US61225M1027 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 75.622M | 112.69M 49.02% | 44.778M -60.26% | 55.983M 25.02% | 45.749M -18.28% | 72.589M 58.67% | 191.84M 164.28% | 563.86M 193.92% | 859.08M 52.36% | |||
| EBITDA YoY % growth | -108.63M -53.54% | -137.089M -26.20% | -72.991M 46.76% | -56.1M 23.14% | -25.5M 54.55% | -112.72M -342.04% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -112.38M -54.20% | -143.311M -27.52% | -81.112M 43.40% | -69.032M 14.89% | -142.093M -105.84% | -157.285M -10.69% | -169.807M -7.96% | -179.198M -5.53% | -106.361M 40.65% | 121.48M 214.22% | 222.77M 83.38% | |
| Operating Margin | N/A | N/A | -107.26% | -61.26% | -317.33% | -280.95% | -371.17% | -246.87% | -55.44% | 21.54% | 25.93% | |
| EPS YoY % growth | -2.29 20.50% | -2.64 -15.28% | -1.02 61.36% | -0.57 43.71% | -1.47 -155.84% | -1.46 0.50% | -1.53 -4.83% | -1.51 1.20% | -0.71 53.10% | 1.38 293.97% | 2.37 71.85% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.39 8.51% | -0.40 -36.67% | -0.39 -268.52% | -0.52 -192.89% |
| Revenue Q2Q % growth | 11.016M 134.63% | 10.725M 16.37% | 11.89M -80.39% | 4.42M -94.80% |
| EBITDA Q2Q % growth | -19.38M 32.44% | -20.4M 0.33% | -35.7M -268.99% | N/A |
| EBIT Q2Q % growth | -31.959M 2.09% | -33.597M -26.65% | -34.378M -364.36% | -41.82M -194.97% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | 0.56 205.66% | -0.34 | 0.90 | 262.91% |
| Q4 2024 Q2Q % growth | 0.23 139.66% | -0.02 | 0.25 | 1,080.39% |
| Q3 2024 Q2Q % growth | -0.29 58.57% | -0.50 | 0.21 | 41.55% |
| Q2 2024 Q2Q % growth | -0.43 39.44% | -0.55 | 0.12 | 21.93% |
| Q1 2024 Q2Q % growth | -0.53 18.46% | -0.58 | 0.05 | 9.30% |
| Q4 2023 Q2Q % growth | -0.58 7.94% | -0.34 | -0.24 | -69.89% |
| Q3 2023 Q2Q % growth | -0.70 -20.69% | -0.74 | 0.04 | 5.18% |
| Q2 2023 Q2Q % growth | -0.71 -24.56% | -0.71 | 0.00 | 0.56% |
| Q1 2023 Q2Q % growth | -0.65 -27.45% | -0.69 | 0.04 | 6.17% |
| Q4 2022 Q2Q % growth | -0.63 32.26% | -0.64 | 0.01 | 0.95% |
| Q3 2022 Q2Q % growth | -0.58 -34.88% | -0.61 | 0.03 | 5.21% |
| Q2 2022 Q2Q % growth | -0.57 84.30% | -0.55 | -0.02 | -3.39% |
| Q1 2022 Q2Q % growth | -0.51 | -0.53 | 0.02 | 4.21% |
| Q4 2021 Q2Q % growth | -0.93 | -0.51 | -0.42 | -82.96% |
| Q3 2021 Q2Q % growth | -0.43 | -0.45 | 0.02 | 4.62% |
| Q2 2021 Q2Q % growth | -3.63 | -0.41 | -3.22 | -784.18% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | 84.929M 7,882.05% | 15.586M | 69.343M | 444.91% |
| Q4 2024 Q2Q % growth | 60.647M | 11.611M | 49.036M | 422.32% |
| Q3 2024 Q2Q % growth | 9.216M | 2.673M | 6.543M | 244.78% |
| Q2 2024 Q2Q % growth | 4.695M | 1.376M | 3.319M | 241.21% |
| Q1 2024 Q2Q % growth | 1.064M | 1.428M | -364K | -25.49% |
| Q4 2023 Q2Q % growth | 15.453M | -15.453M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -7.49% | 0% | 62.38% |
| Revenue | 0% | -24.21% | 0% | 66.76% |